
Roche licences antiviral nucleoside from Atea
Under the agreement, Roche will pay US$350m in cash for ex US-distribution of Atea Pharmaceuticals antiviral Phase II candidate. Atea has the option...

Avantium NV bags money for demo plant
The new grant is part of a €30m financing mix that Avantium and the Groningen consortium announced this January. FDCA is the key building block for...

European Circular Bioeconomy Fund growing
Nurition world market leader Nestlé as well as Neste Oyj, Volkswohl Bund Versicherungen, NRW.BANK and an undisclosed family office contributed to the...

Immunocore bags US$75m in Series C round
The round included support from existing investors and funds and accounts managed by BlackRock. Immunocore said it will use the proceeds to ...

Moderna to file for EU approval of mRNA-1273 vaccine
Modernas primary analysis of the COVE Phase III data was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus...

Cell and gene therapy specialist Minaris expanding
In Europe, the Showa Denko Materials Co., Ltd. subsidiary will invest US$40.7 million to build a new state-of-the-art facility in proximity to an...

BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...